Sanara MedTech Inc SMTI Stock Analysis

About Sanara MedTech Inc

Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. The Company markets, distributes and develops surgical, wound and skincare products for use by physicians and clinicians in hospitals, clinics and all post-acute care settings and offers wound care and dermatology virtual consultation services via telemedicine. Sanara’s products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara markets and distributes CellerateRX ® Surgical Activated Collagen, FORTIFY TRG ® Tissue Repair Graft and FORTIFY FLOWABLE ® Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN ™ Verified Inductive Bone Matrix, ALLOCYTE ® Plus Advanced Viable Bone Matrix, BiFORM ® Bioactive Moldable Matrix, TEXAGEN ® Amniotic Membrane Allograft, and BIASURGE ® Advanced Surgical Solution to the surgical market. In addition, the following products are sold in the wound care market: BIAKŌS ® Antimicrobial Skin and Wound Cleanser, BIAKŌS ® Antimicrobial Wound Gel, and BIAKŌS ® Antimicrobial Skin and Wound Irrigation Solution. Sanara’s pipeline also contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement and cell compatible substrates. The Company believes it has the ability to drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost.